Navigation Links
Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease
Date:1/21/2009

HAMBURG, Germany and STOCKHOLM, January 21 /PRNewswire/ -- Richter-Helm BioLogics GmbH & Co. KG and Athera Biotechnologies AB have signed an agreement for the development and manufacturing of Athera's novel product for prevention of plaque rupture and athero-thrombosis through binding of the protein, Annexin A5, to endothelium. The recombinant protein Annexin A5 is intended for the treatment of patients with Acute Coronary Syndrome and who are at imminent risk for Myocardial Infarction.

This agreement secures a highly cost efficient long-term development and manufacturing plan for Athera, including possible future large volume commercial production. Annexin A5 is a biotechnology product produced using Richter-Helm's proprietary E. coli based expression system. Richter-Helm will initiate strain and process development of the new process, reaching a 1000 litre production scale.

"The Annexin A5 project fits well with the competence and experience of our company. We are confident that our collaboration will be as efficient and constructive as our negotiations were. Our state-of-the-art facilities are ideal for producing the high-quality Annexin A5 required to comply with the standards of the regulatory agencies," stated Dr. Bert Behnke, Managing Director of Richter-Helm.

"We are very pleased to get Richter-Helm as our development partner, they have an excellent reputation. We have now secured cost competitive and high quality production for clinical and commercial use," said Carina Schmidt, CEO of Athera Biotechnologies.

About Richter-Helm

Richter-Helm is a dynamic and expanding biotechnology company located at three sites in Northern Germany. The company was founded in 1997 as Strathmann Biotec and was acquired by a joint-venture of Gedeon Richter Plc, Hungary and Helm AG, Germany in 2007. The company operates a development facility and two cGMP manufacturing facilities for microbial production. Richter-Helm offers highly specialised contract development and manufacturing services for the pharmaceutical and biotechnological industries. Additionally, Richter-Helm is seeking for interesting biopharmaceutical development projects for its own pipeline and for co-development with partners.http://www.richter-helm.eu

    Contact:
    Dr. Kai Pohlmeyer, Head of Business Development
    Phone: +49-40-2375-1430
    Mail: k.pohlmeyer@richter-helm-biotec.eu

About Athera Biotechnologies

Athera provides new opportunities for treatment and prevention of cardiovascular disease. The company has an innovative pipeline of drug candidates and risk markers enabling a possibility to provide a true combination of diagnosis and treatment. On Oct 2, 2008 Athera announced a collaboration with Dyax Corp. (NASDAQ: DYAX) to discover and develop antibodies for treatment of cardiovascular inflammation. The therapy is based on phosphorylcholine (PC) and low levels of antibodies to PC in human serum have been linked with an increased risk of developing cardiovascular disease. Athera Biotechnologies is based in Karolinska Institutet Science Park in Stockholm and main investors include Karolinska Development and Baltic Sea Foundation. Athera is also a major partner in the highly ranked EU-project CVDIMMUNE lead by Karolinska Institutet. The project involves 10 academic and industrial partners, also including TNO, Phadia GmbH and Johannes Gutenberg-University Mainz. http://www.athera.se

    Contact:
    Carina Schmidt, CEO
    Phone: +46705525115
    Mail: c.schmidt@athera.se


'/>"/>
SOURCE Richter-Helm BioLogics GmbH & Co. KG and Athera Biotechnologies AB
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Athera Biotechnology Founder Johan Frostegard and His Colleagues Win NACB Distinguished Abstract Award at AACC 2008
2. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
3. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
4. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
5. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
6. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
7. Amyris Biotechnologies Announces $70 Million Series B Round
8. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
9. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
10. Maven Biotechnologies, LLC to Present at BIOCOM Investor Conference
11. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... ... August 22, 2017 , ... Cutting Edge ... of highly differentiated spinal implant technologies, announced today the appointment of Luke Maher ... spinal device industry experience to directing Cutting Edge Spine’s national sales force, including ...
(Date:8/22/2017)... ... 2017 , ... KBioBox is pleased to announce the creation ... ananlysis. KBioBox has adapted their core technology and direct alignment algorithms to extend ... understand reports, extended indel analysis, and translocation analysis. , “The extended GUIDE-Seq analysis ...
(Date:8/21/2017)... ... 2017 , ... MacArthur Sotheby’s International Realty, a luxury real ... the first Delos Wellness Signature™ residence in Hawaii is on the market for ... listing agent Kelly Allen, R(S) of Carvill Sotheby’s International Realty located on Oahu, ...
(Date:8/21/2017)... ... August 21, 2017 , ... Baltimore ... bio security firm, to bring its proprietary CANARY pathogen detection technology and high ... the Chinese firm has purchased an undisclosed number of PathSensors’ Zephyr pathogen detection ...
Breaking Biology Technology:
(Date:5/23/2017)... the first robotic gym for the rehabilitation and functional motor sense evaluation ... Genoa, Italy . The first 30 robots will be available from ... . The technology was developed and patented at the IIT laboratories ... Technology thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:5/16/2017)... 16, 2017   Bridge Patient Portal , ... MD EMR Systems , an electronic medical ... GE, have established a partnership to build an ... the GE Centricity™ products, including Centricity Practice Solution ... These new integrations will allow healthcare delivery ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
Breaking Biology News(10 mins):